CIMAAS
CiMaas develops therapies engaging the immune system for the treatment of a growing population facing cancer that cannot be cured by the current standard of care. A better cure relates to safe technology taking away several of the severe side-effects of current therapies. By doing so, the company will create quality value for patients and share holders.
CIMAAS
Industry:
Biotechnology Health Care Product Research Therapeutics Wellness
Founded:
2015-01-01
Address:
Maastricht, Limburg, The Netherlands
Country:
The Netherlands
Website Url:
http://www.cimaas.com
Total Employee:
1+
Status:
Active
Contact:
31 (0)43 388 5816
Technology used in webpage:
Microsoft Exchange Online Person Schema Facebook Sharer Gravatar Profiles
Similar Organizations
ActoBio Therapeutics
ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs.
BioSerenTach
BioSerenTach Inc delivers antigens directly to Langerhans cells of the immune system.
Captain T Cell
Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients.
HerbalGem
Herbalgem develops gemmotherapy remedies and herbal extracts.
Klahas
Klahas is developing nanosensors for gas detection.
SalvaRx Ltd.
SalvaRx Ltd. develops therapies within the rapidly growing immuno-oncology market.
Current Employees Featured
Founder
Official Site Inspections
http://www.cimaas.com Semrush global rank: 6.04 M Semrush visits lastest month: 1.35 K
- Host name: n9117b2.lb.shared.prod.hostnet.nl
- IP address: 91.184.0.52
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "CiMaas"
About CiMaas - Cimaas
For this, CiMaas develops therapies engaging the immune system for the treatment of a steadily growing population facing cancer that cannot be cured by the current standard of care. A better cure relates to safe technology taking …See details»
CiMaas - Crunchbase Company Profile & Funding
CiMaas develops therapies engaging the immune system for the treatment of a growing population facing cancer that cannot be cured by the current standard of care. A better cure relates to safe technology taking away several of the …See details»
EXECUTIVE SUMMARY CiMaas
E: [email protected] Gerard MJ Bos, CEO T: +31-6-10711914 E: [email protected] W: www.cimaas.com Addresses: Main office Oxfordlaan 70, 6229 EV Maas-tricht | P.O. Box …See details»
CiMaas - Overview, News & Similar companies | ZoomInfo.com
CiMaas aims to develop cellular immunotherapy for specific groups of cancer patients. The company develops unique products based on cells and antib odies from the immune system. …See details»
CiMaas Company Profile 2024: Valuation, Funding
CiMaas General Information Description. Developer of immunotherapy designed to cure specific types of cancer. The company's technology engages the immune system for the treatment of a steadily growing population facing cancer that …See details»
CiMaas Company Profile - Office Locations, Competitors, Revenue …
CiMaas is a company that develops immunotherapy for cancer by engaging the immune system. It focuses on the development of a cancer vaccine using the patient's own immune (dendritic) …See details»
CiMaas BV: Drug pipelines, Patents, Clinical trials - Synapse
Explore CiMaas BV with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Hemic and Lymphatic Diseases, Immune System Diseases, Neoplasms ...See details»
CiMaas - Crunchbase
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.See details»
CiMaas - VentureRadar
CiMaas develops immunotherapy for cancer by optimally engaging the immune system. First of all, CiMaas is developing a dendritic cell vaccine using its proprietary maturation technology. …See details»
Amsterdam’s 819 Capital Partners acquires Dutch biotech startup …
Dec 2, 2024 Amsterdam-based venture capital firm 819 Capital Partners announced that it has acquired and invested in CiMaas, a Dutch biotech company specialising in Natural Killer (NK) …See details»
CiMaas Team - Cimaas
Prof Dr Gerard Bos Chief: Executive Officer/Co-founder, Dr Wilfred Germeraad: Chief Scientific Officer/Co-founderSee details»
CiMaas - Products, Competitors, Financials, Employees, …
CiMaas BV Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and …See details»
CiMaas - Contacts, Employees, Board Members, Advisors
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.See details»
CiMaas - Company Profile - Tracxn
Nov 14, 2024 CiMaas - Developer of immunotherapeutics for cancer treatment. Raised funding over 1 round from 1 investor. Founded by Gerard M J Bos and Wilfred T V Germeraad in the …See details»
CiMaas – cellular immonotherapy | Biotech 365
Recently, CiMaas BV and PharmaCell BV enter a collaborative agreement. Ci-Maas and PharmaCell BV, a leading Contract Manufacturing Organization for Cellular Therapies and …See details»
Investors - Cimaas
The CiMaas Business Plan is available to interested investors. Please contact us for further information. You can also directly schedule an appointment. Latest news. CiMaas moves into …See details»
☑️Cimaas — Consulting Organization from the
Cimaas — Consulting Organization from the Netherlands, has experience with Horizon 2020 (2014 - 2020), Horizon Europe (2021 - 2027), it`s involved in Health, Research sectors. Our …See details»
New therapeutic concepts - Cimaas
CiMaas has developed a new NK cell expansion technology to provide the capability for the treatment of cancer patients with very high numbers of donor derived Natural Killer cells (“NK …See details»
Pipeline - Cimaas
Secondly, CiMaas has developed an NK cell product. The expansion technology functions as a platform for treatment of many types of cancer. Currently, we are capable of expanding NK …See details»